Known targets — ChEMBL curated mechanism
CYP11A1CYP11B1CYP11B2CYP17A1ERG11
The experimentally established mechanism targets of Levoketoconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 known ✓ | P05093 | 15/20 | 0.88 |
| ▸ | CYP11B1 known ✓ | P15538 | 14/20 | 0.88 |
| ▸ | CYP11B2 known ✓ | P19099 | 1/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 19/20 | 0.88 |
| ▸ | CYP21A2 | P08686 | 16/20 | 0.88 |
| ▸ | CYP19A1 | P11511 | 16/20 | 0.88 |
| ▸ | USP2 | O75604 | 2/20 | 0.88 |
| ▸ | MAPT | P10636 | 2/20 | 0.88 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.88 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.88 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.88 |
| ▸ | MEN1 | O00255 | 1/20 | 0.88 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.88 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.88 |
| ▸ | CYP27B1 | O15528 | 1/20 | 0.88 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.88 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.88 |
| ▸ | GMNN | O75496 | 1/20 | 0.88 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.88 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levoketoconazole SCHEMBL7175329 | 0.94 | CYP3A4 (0.92) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL13575830 | 0.94 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL1517472 | 0.94 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL13606596 | 0.94 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL41473 | 0.94 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL24312989 | 0.94 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL8407 | 0.94 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Ketoconazole SCHEMBL8408 | 0.94 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Ketoconazole SCHEMBL18258319 | 0.94 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL29384825 | 0.94 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3949962-B1 | COMPOSITIONS AGAINST CANDIDA INFECTIONS | UNIV LEUVEN KATH (BE) | 2023-09-13 | — | — | EP | disclosed |
| EP-3949962-A1 | COMPOSITIONS AGAINST CANDIDA INFECTIONS | Katholieke Universiteit Leuven (BE) | 2022-02-09 | — | — | EP | disclosed |
| EP-3468599-A2 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3469000-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3468996-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3468615-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3468993-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3468598-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3468616-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3468596-A2 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| WO-2012012759-A2 | ANTI-TUMOR ANTIGEN ANTIBODIES AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2011140254-A1 | ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND USES THEREOF | ADIMAB, LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011047180-A1 | BISPECIFIC BINDING AGENTS TARGETING IGF-1R AND ERBB3 SIGNALLING AND USES THEREOF | MERRIMACK PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011022727-A2 | ANTIBODIES AGAINST THE ECTODOMAIN OF ERBB3 AND USES THEREOF | MERRIMACK PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
| CN-101674846-A | Antibodies against erbb3 and uses thereof | MERRIMACK PHARMACEUTICALS INC | 2010-03-17 | — | — | CN | disclosed |
| EP-2129396-A2 | ANTIBODIES AGAINST ERBB3 AND USES THEREOF | Merrimack Pharmaceuticals, Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008100624-A2 | ANTIBODIES AGAINST ERBB3 AND USES THEREOF | MERRIMACK PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| CN-1481797-A | Composition comprising ketoconazole and sultifen | 重庆华邦制药股份有限公司 | 2004-03-17 | — | — | CN | disclosed |
| US-6632921-B1 | Administering as topical fungicide against Candida | G. D SEARLE & CO | 2003-10-14 | — | — | US | disclosed |
| US-5942600-A | COMPOUNDS WITH SELECTIVE CONTROL OF FUNGAL ORGANISM CANDIDA ALBICANS FOR TREATMENT IN HUMANS, FOR EXAMPLE THOSE WITH WEAKENED IMMUNE SYSTEMS DUE TO AIDS; SPECIES-SPECIFIC CONTROL | G. D. SEARLE & CO. (US) | 1999-08-24 | — | — | US | disclosed |